How does the noncleavable linker in the anti-Rat IgG(Fc)Fab-N-MMAF ADC contribute to its stability?

The noncleavable linker in this ADC ensures that the cytotoxic MMAF remains attached to the Fab fragment throughout circulation in the bloodstream. This increases the stability of the ADC, reducing the risk of premature drug release and off-target toxicity, thereby enhancing the safety and efficacy of the ADC in experimental settings.

What are the key benefits of using the anti-Rat IgG(Fc)Fab-N-MMAF ADC in research?

This ADC offers several benefits, including its lack of obvious toxicity without a primary antibody, making it a safer option for pre-screening rat monoclonal antibodies as ADC candidates. Additionally, it is an economical alternative, providing researchers with a reliable tool for assessing potential ADC candidates without incurring high costs.

What experimental applications is the anti-Rat IgG(Fc)Fab-N-MMAF ADC best suited for?

This ADC is particularly well-suited for applications that involve the pre-screening of rat monoclonal antibodies for potential use in ADC development. Its specific targeting of the rat IgG Fc region and its stability due to the noncleavable linker make it ideal for these preliminary screening processes.

How does the anti-Rat IgG(Fc)Fab-N-MMAF ADC reduce off-target toxicity?

The ADC reduces off-target toxicity through its noncleavable linker, which ensures that the MMAF cytotoxic agent remains attached to the Fab fragment until internalized by the target cells. This targeted delivery minimizes the release of the cytotoxic agent into non-target cells, reducing unintended toxic effects.

What role does the Fc region play in the anti-Rat IgG(Fc)Fab-N-MMAF ADC's mechanism of action?

The Fc region in this ADC is critical for binding to cell receptors and complement proteins, mediating physiological effects such as ADCC and opsonization. This binding facilitates the delivery of the cytotoxic agent to the target cells, enhancing the ADC's overall efficacy in inducing cell death in specific cell populations.

What is the primary function of the Fab fragment in the anti-Rat IgG(Fc)Fab-N-MMAF ADC?

The Fab fragment in this ADC is derived from a secondary antibody that specifically targets the Fc region of rat IgG. Its primary function is to bind selectively to the rat IgG Fc region, allowing the attached cytotoxic MMAF molecule to be delivered specifically to target cells. This selective binding enhances the precision and effectiveness of the ADC in research applications.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-Rat IgG(Fc)Fab-N-MMAF ADC

anti-Rat IgG(Fc)Fab-N-MMAF ADC (CAT#: ADC-AA-041)

This ADC product is comprised of a Fab fragment of an anti-rat IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF. The antibody portion is a Fab fragment of a secondary antibody and the drug portion, MMAF, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
Fab fragment of anti-rat IgG Fc specific polyclonal antibody

Species Reactivity
Rat

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
MMAF (Monomethyl auristatin F)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-041. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

We've been very satisfied with the anti-Rat IgG(Fc)Fab-N-MMAF ADC from Creative Biolabs. The product's specificity and low toxicity make it an excellent choice for pre-screening rat monoclonal antibodies.

Excellent

This ADC product has proven to be both cost-effective and safe for our screenings. The low toxicity profile is a major plus, allowing us to conduct more thorough and accurate research.

Excellent

Creative Biolabs' anti-Rat IgG(Fc)Fab-N-MMAF ADC offers excellent performance with minimal toxicity. It's a powerful tool that has streamlined our antibody candidate evaluations.

Excellent

Using the anti-Rat IgG(Fc)Fab-N-MMAF ADC has significantly improved our lab's efficiency. The product's cytotoxicity and safety make it an invaluable resource for our pre-screening processes.

Excellent

We've found Creative Biolabs' anti-Rat IgG(Fc)Fab-N-MMAF ADC to be highly effective. Its balanced combination of efficacy and safety has made it a preferred choice in our research workflow.

Q: 1: How does the noncleavable linker in the anti-Rat IgG(Fc)Fab-N-MMAF ADC contribute to its stability?
A: The noncleavable linker in this ADC ensures that the cytotoxic MMAF remains attached to the Fab fragment throughout circulation in the bloodstream. This increases the stability of the ADC, reducing the risk of premature drug release and off-target toxicity, thereby enhancing the safety and efficacy of the ADC in experimental settings.
Q: 2: What are the key benefits of using the anti-Rat IgG(Fc)Fab-N-MMAF ADC in research?
A: This ADC offers several benefits, including its lack of obvious toxicity without a primary antibody, making it a safer option for pre-screening rat monoclonal antibodies as ADC candidates. Additionally, it is an economical alternative, providing researchers with a reliable tool for assessing potential ADC candidates without incurring high costs.
Q: 3: What experimental applications is the anti-Rat IgG(Fc)Fab-N-MMAF ADC best suited for?
A: This ADC is particularly well-suited for applications that involve the pre-screening of rat monoclonal antibodies for potential use in ADC development. Its specific targeting of the rat IgG Fc region and its stability due to the noncleavable linker make it ideal for these preliminary screening processes.
Q: 4: How does the anti-Rat IgG(Fc)Fab-N-MMAF ADC reduce off-target toxicity?
A: The ADC reduces off-target toxicity through its noncleavable linker, which ensures that the MMAF cytotoxic agent remains attached to the Fab fragment until internalized by the target cells. This targeted delivery minimizes the release of the cytotoxic agent into non-target cells, reducing unintended toxic effects.
Q: 5: What role does the Fc region play in the anti-Rat IgG(Fc)Fab-N-MMAF ADC's mechanism of action?
A: The Fc region in this ADC is critical for binding to cell receptors and complement proteins, mediating physiological effects such as ADCC and opsonization. This binding facilitates the delivery of the cytotoxic agent to the target cells, enhancing the ADC's overall efficacy in inducing cell death in specific cell populations.
Q: 6: What is the primary function of the Fab fragment in the anti-Rat IgG(Fc)Fab-N-MMAF ADC?
A: The Fab fragment in this ADC is derived from a secondary antibody that specifically targets the Fc region of rat IgG. Its primary function is to bind selectively to the rat IgG Fc region, allowing the attached cytotoxic MMAF molecule to be delivered specifically to target cells. This selective binding enhances the precision and effectiveness of the ADC in research applications.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-054	Protein A-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-029	anti-MIgG(Fc)Fab-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-052	Protein A-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)

CAT#	Product Name	Linker	Payload
ADC-AA-001	anti-HIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-039	anti-Rat IgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-045	anti-Rat IgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-046	anti-Rat IgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-018	anti-HIgG(Fab)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-AA-010	anti-HIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-049	Protein G-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-020	anti-MIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-001	anti-HIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-009	anti-HIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.